Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

15 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Pancreatic Effects of Liraglutide or Sitagliptin in Overweight Patients With Type 2 Diabetes: A 12-Week Randomized, Placebo-Controlled Trial.
Smits MM, Tonneijck L, Muskiet MH, Kramer MH, Pieters-van den Bos IC, Vendrik KE, Hoekstra T, Bruno MJ, Diamant M, van Raalte DH, Cahen DL. Smits MM, et al. Among authors: pieters van den bos ic. Diabetes Care. 2017 Mar;40(3):301-308. doi: 10.2337/dc16-0836. Epub 2016 Dec 20. Diabetes Care. 2017. PMID: 27998910 Clinical Trial.
Twelve week liraglutide or sitagliptin does not affect hepatic fat in type 2 diabetes: a randomised placebo-controlled trial.
Smits MM, Tonneijck L, Muskiet MH, Kramer MH, Pouwels PJ, Pieters-van den Bos IC, Hoekstra T, Diamant M, van Raalte DH, Cahen DL. Smits MM, et al. Among authors: pieters van den bos ic. Diabetologia. 2016 Dec;59(12):2588-2593. doi: 10.1007/s00125-016-4100-7. Epub 2016 Sep 15. Diabetologia. 2016. PMID: 27627981 Free PMC article. Clinical Trial.
Glucagon-like peptide-1 receptor agonist exenatide has no acute effect on MRI-measured exocrine pancreatic function in patients with type 2 diabetes: a randomized trial.
Smits MM, Tonneijck L, Muskiet MH, Kramer MH, Diamant M, Pieters-van den Bos IC, van Raalte DH, Cahen DL. Smits MM, et al. Among authors: pieters van den bos ic. Diabetes Obes Metab. 2016 Mar;18(3):281-8. doi: 10.1111/dom.12612. Epub 2016 Jan 13. Diabetes Obes Metab. 2016. PMID: 26640129 Clinical Trial.
Relationship between pretreatment FDG-PET and diffusion-weighted MRI biomarkers in diffuse large B-cell lymphoma.
de Jong A, Kwee TC, de Klerk JM, Adam JA, de Keizer B, Fijnheer R, Kersten MJ, Ludwig I, Jauw YW, Zijlstra JM, Pieters-Van den Bos IC, Stoker J, Hoekstra OS, Nievelstein RA. de Jong A, et al. Among authors: pieters van den bos ic. Am J Nucl Med Mol Imaging. 2014 Apr 25;4(3):231-8. eCollection 2014. Am J Nucl Med Mol Imaging. 2014. PMID: 24795837 Free PMC article.
Magnetic resonance imaging in the evaluation of (deep infiltrating) endometriosis: the value of diffusion-weighted imaging.
Busard MP, Mijatovic V, van Kuijk C, Pieters-van den Bos IC, Hompes PG, van Waesberghe JH. Busard MP, et al. J Magn Reson Imaging. 2010 May;31(5):1117-23. doi: 10.1002/jmri.22139. J Magn Reson Imaging. 2010. Corrected and republished in: J Magn Reson Imaging. 2010 Oct;32(4):1003-9. doi: 10.1002/jmri.22310 PMID: 20432346 Corrected and republished.
Comparison of modern and conventional imaging techniques in establishing multiple myeloma-related bone disease: a systematic review.
Regelink JC, Minnema MC, Terpos E, Kamphuis MH, Raijmakers PG, Pieters-van den Bos IC, Heggelman BG, Nievelstein RJ, Otten RH, van Lammeren-Venema D, Zijlstra JM, Arens AI, de Rooy JW, Hoekstra OS, Raymakers R, Sonneveld P, Ostelo RW, Zweegman S. Regelink JC, et al. Among authors: pieters van den bos ic. Br J Haematol. 2013 Jul;162(1):50-61. doi: 10.1111/bjh.12346. Epub 2013 Apr 25. Br J Haematol. 2013. PMID: 23617231 Free article.
15 results